CATALYST PHARMACEUTICA

Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®

28 Jun 2021 15:30:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan

28 Jun 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

03 Jun 2021 12:20:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

19 May 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

10 May 2021 16:29:53 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021

03 May 2021 07:05:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program

22 Mar 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

15 Mar 2021 16:26:27 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021

04 Mar 2021 10:00:03 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021

22 Feb 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update

06 Jan 2021 07:07:00 By Nasdaq GlobeNewswire